已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Chinese Neurosurgical Randomized Controlled Trials: Dynamics in Trial Implementation and Completion

医学 随机对照试验 梅德林 神经外科 科克伦图书馆 大流行 报告审判综合标准 临床试验 2019年冠状病毒病(COVID-19) 重症监护医学 外科 疾病 内科学 政治学 传染病(医学专业) 法学
作者
Tao Liu,Mingqi Liu,Zhuang Sha,Chenrui Wu,Zhihao Zhao,Jiangyuan Yuan,Dongyi Feng,Meng Nie,Rongcai Jiang
出处
期刊:Neurosurgery [Lippincott Williams & Wilkins]
被引量:2
标识
DOI:10.1227/neu.0000000000002702
摘要

BACKGROUND AND OBJECTIVES: The focus on evidence-based neurosurgery has led to a considerable amount of neurosurgical evidence based on randomized controlled trials (RCTs) being published. Nevertheless, there has been no systematic appraisal of China's contribution to RCTs. Information about the changes in characteristics of Chinese neurosurgical RCTs before and during the COVID-19 pandemic is limited. This study aims to perform a detailed examination and comprehensive analysis of the characteristics of Chinese neurosurgical RCTs and to examine the differences before and during the COVID-19 pandemic. METHODS: We conducted a comprehensive database search including PubMed, Web of Science, Embase, and Cochrane Library up to March 2023, with a criterion of inclusion based on an impact factor above 0. We subsequently examined the design and quality parameters of the included RCTs and assessed the differences before and during the COVID-19 pandemic (based on follow-up ending before or after January 2020). Moreover, we investigated potential factors that may affect the quality and developmental trends of neurosurgical RCTs in China. RESULTS: The main focus of the 91 neurosurgical RCTs was vascular disease (47.3%) and trauma (18.7%). Over half of the trials used Consolidated Standards of Reporting Trial diagrams (69.2%), and the majority compared nonsurgical treatments (63.7%). Larger trials tended to have better quality scores, but those with significant efficacy were less likely to have power calculations. Over time, there was an increase in the use of Consolidated Standards of Reporting Trial diagrams and well-specified outcomes. The COVID-19 pandemic may have hindered the completion of neurosurgical RCTs in China, but it has had little impact on the design and quality so far. CONCLUSION: Chinese neurosurgeons have made significant progress in advancing neurosurgical RCTs despite challenges. However, shortcomings in sample size and power calculation need attention. Improving the rigor, rationality, and completeness of neurosurgical RCT design is crucial.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
4秒前
ROSA完成签到,获得积分10
4秒前
yjj发布了新的文献求助10
4秒前
wanci应助小斌采纳,获得10
6秒前
无花果应助ZH的天方夜谭采纳,获得10
6秒前
YueYue完成签到,获得积分10
7秒前
Akim应助龚贤亮采纳,获得10
8秒前
8秒前
赖赖发布了新的文献求助10
13秒前
15秒前
万能图书馆应助mujinxin采纳,获得10
16秒前
从容芮应助爱吃卷饼采纳,获得50
17秒前
17秒前
李健应助蜂鸟5156采纳,获得10
18秒前
19秒前
yjj完成签到,获得积分10
19秒前
元问晴完成签到,获得积分10
20秒前
lingzhiyi完成签到,获得积分10
21秒前
23秒前
23秒前
可个可可发布了新的文献求助10
23秒前
科研通AI6应助十年饮冰采纳,获得10
24秒前
25秒前
zimo发布了新的文献求助10
26秒前
小巧的不评完成签到 ,获得积分10
27秒前
勤恳平卉完成签到,获得积分10
27秒前
今后应助董若兰采纳,获得10
27秒前
十月发布了新的文献求助30
27秒前
alpv完成签到,获得积分10
28秒前
mujinxin发布了新的文献求助10
29秒前
30秒前
孤标傲世完成签到 ,获得积分10
31秒前
俭朴的跳跳糖完成签到 ,获得积分10
33秒前
爆米花应助默默襄采纳,获得10
34秒前
壮观寒荷完成签到,获得积分10
34秒前
mujinxin完成签到,获得积分10
35秒前
zhouzhou发布了新的文献求助10
36秒前
38秒前
39秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Einführung in die Rechtsphilosophie und Rechtstheorie der Gegenwart 1500
Cancer Systems Biology: Translational Mathematical Oncology 1000
Binary Alloy Phase Diagrams, 2nd Edition 1000
NMR in Plants and Soils: New Developments in Time-domain NMR and Imaging 600
Electrochemistry: Volume 17 600
La cage des méridiens. La littérature et l’art contemporain face à la globalisation 577
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 4957586
求助须知:如何正确求助?哪些是违规求助? 4218964
关于积分的说明 13132165
捐赠科研通 4001830
什么是DOI,文献DOI怎么找? 2190033
邀请新用户注册赠送积分活动 1204936
关于科研通互助平台的介绍 1116538